Hospital District No. 1 of Dickinson County, Kansas
Hospital District No. 1 of Dickinson County, Kansas was paid $654K by Medicaid between Jan 2018 and Nov 2024, across 64 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoHOSPITAL DISTRICT NO. 1 OF DICKINSON COUNTY, KANSAS
ABILENE, KS 67410
ABILENE, KS 67410
33aNPI1992759633assigned 05/19/2006
33bProvider typeRegistered Dietitian
28Total paid$654K
24GClaims33,651
24DCodes billed64
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Registered Dietitian providers in Kansas
Rank by total paid#2 of 5
Median peer was paid$89K
This provider vs. median7.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,388 | $161K | |
| 2019 | 7,094 | $129K | |
| 2020 | 6,683 | $77K | |
| 2021 | 6,172 | $107K | |
| 2022 | 2,922 | $88K | |
| 2023 | 1,534 | $49K | |
| 2024incomplete | 858 | $43K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 3,890 | 2,581 | $147K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 5,528 | 3,969 | $117K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.3% | 1,553 | 905 | $61K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.4% | 1,556 | 1,096 | $42K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.9% | 214 | 207 | $32K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.7% | 312 | 291 | $18K |
| 80345 | 2.3% | 633 | 352 | $15K | |
| 80355 | 2.0% | 1,095 | 1,026 | $13K | |
| 80366 | 2.0% | 1,095 | 1,026 | $13K | |
| 80346 | 1.9% | 376 | 352 | $12K | |
| 80361 | 1.8% | 636 | 352 | $11K | |
| 80371 | 1.7% | 1,096 | 1,027 | $11K |
52 more codes
| 80349 | 1.7% | 929 | $11K | |
| 80358 | 1.6% | 375 | $10K | |
| 80352 | 1.6% | 863 | $10K | |
| 80053 | Comprehensive metabolic panel | 1.5% | 1,135 | $10K |
| 80348 | 1.5% | 375 | $10K | |
| 80321 | 1.3% | 325 | $9K | |
| 80324 | 1.3% | 577 | $8K | |
| 80306 | 1.2% | 358 | $8K | |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 561 | $7K |
| 82542 | 1.1% | 1,266 | $7K | |
| 80362 | 1.0% | 1,112 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 97 | $7K |
| 80369 | <1% | 374 | $5K | |
| 80354 | <1% | 375 | $5K | |
| 80356 | <1% | 375 | $5K | |
| 80353 | <1% | 374 | $5K | |
| 80372 | <1% | 356 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 92 | $4K |
| 80365 | <1% | 221 | $4K | |
| 0240U | <1% | 19 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 92 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 851 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 129 | $3K |
| 83992 | <1% | 78 | $2K | |
| 99285 | Emergency room visit (most serious) | <1% | 40 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 67 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 23 | $856.79 |
| 81001 | <1% | 204 | $773.02 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 60 | $671.98 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 54 | $646.70 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 51 | $336.55 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 51 | $325.24 |
| J3490 | Unclassified drugs | <1% | 75 | $223.56 |
| 80373 | <1% | 12 | $197.50 | |
| 99070 | <1% | 169 | $155.73 | |
| 87184 | <1% | 30 | $153.48 | |
| 87077 | <1% | 30 | $152.94 | |
| 87081 | <1% | 13 | $121.74 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 34 | $114.77 |
| 85610 | <1% | 74 | $113.75 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 78 | $97.18 |
| 86140 | <1% | 16 | $81.24 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 39 | $73.46 |
| 85652 | <1% | 16 | $63.37 | |
| 80305 | <1% | 788 | $42.33 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21 | $38.79 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,407 | $29.65 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 573 | $10.40 |
| A4335 | Incontinence supply; miscellaneous | <1% | 28 | $3.89 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 286 | $0.00 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 105 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAVERLY, KIMBERLY (CEO)
| Provider | Location | Paid |
|---|---|---|
| Hospital District No. 1 of Dickinson County, Kansas | Abilene, KS | $1.59M |
| Hospital District No. 1 of Dickinson County, Kansas | Abilene, KS | $62K |
| Hospital District No. 1 of Dickinson County, Kansas | Abilene, KS | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.